Cargando…
PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
BACKGROUND: Poor immunogenicity and extensive immunosuppressive T-cell infiltration in the tumor immune microenvironment (TIME) have been identified as potential barriers to immunotherapy success in “immune-cold” breast cancers. Thus, it is crucial to identify biomarkers that can predict immunothera...
Autores principales: | Dong, Hongmei, Xie, Chaoyu, Yao, Zhimeng, Zhao, Ruijun, Lin, Yusheng, Luo, Yichen, Chen, Shuanglong, Qin, Yanfang, Chen, Yexi, Zhang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393709/ https://www.ncbi.nlm.nih.gov/pubmed/36003382 http://dx.doi.org/10.3389/fimmu.2022.947841 |
Ejemplares similares
-
PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer
por: Zhao, Ruijun, et al.
Publicado: (2023) -
Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022) -
Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment
por: Yao, Zhimeng, et al.
Publicado: (2023) -
Comprehensively Analyze the Prognosis Significance and Immune Implication of PTPRO in Lung Adenocarcinoma
por: Lin, Zhimin, et al.
Publicado: (2023) -
CD8(+) T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2022)